Benign Migratory Glossitis in a Patient With Cholangiocarcinoma due to Targeted Drug Therapy
Sandeep Gurav1, Gurkaran Preet Singh1, Radhika Jain1
1Dental and Prosthetic Surgery, Tata Memorial Hospital A CI of Homi Bhabha National Institute Mumbai India.
Clinical Case Reports
|June 8, 2026
Abstract:
During the course of targeted drug therapy, a cancer patient may manifest a myriad of systemic and oral toxicities. This has a direct impact on the patient's QOL. This clinical image highlights a rarely-encountered oral mucosal alteration called benign migratory glossitis in a case of cholangiocarcinoma who was subjected to bevacizumab.
